Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Pulmatrix Inc    PULM

PULMATRIX INC (PULM)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/14/2018 06/15/2018 06/18/2018 06/19/2018 06/20/2018 Date
0.5663(c) 0.5846(c) 0.5666(c) 0.555(c) 0.530317(c) Last
2 341 722 1 080 494 1 046 244 1 401 687 1 241 724 Volume
-3.69% +3.23% -3.08% -2.05% -4.45% Change
More quotes
Company
Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the discovery and development of novel inhaled therapeutic products.The company focuses on the prevention and treatment of respiratory diseases and infections.It offers products based on its proprietary dry powder delivery... 
More about the company
Latest news on PULMATRIX INC
06/14PULMATRIX : Announces Publication of Results from a Phase 1 Pharmacodynamic Stud..
AQ
06/07PULMATRIX : Announces Approval of Proposals Submitted to Company's Stockholders
PR
06/07PULMATRIX, INC. : Material Modification to Rights of Security Holders, Change in..
AQ
05/25PULMATRIX : selected to present company profile at the 2018 Respiratory Innovati..
AQ
05/25PULMATRIX, INC. : Other Events (form 8-K)
AQ
05/18PULMATRIX : selected to present company profile at the 2018 Respiratory Innovati..
AQ
05/11PULMATRIX, INC. (NASDAQ : PULM) Files An 8-K Results of Operations and Financial..
AQ
05/11PULMATRIX : Management's Discussion and Analysis of Financial Condition and Resu..
AQ
05/11PULMATRIX, INC. : Results of Operations and Financial Condition, Financial State..
AQ
05/11PULMATRIX : Reports Q1 2018 Results
PR
More news
Sector news : Bio Therapeutic Drugs
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
06/20Latecomer Sanofi looks to catch next wave of cancer therapies
RE
06/19Alexion Uses FDA Priority-Review Voucher for Blood Disorder
DJ
06/13Sanofi says on track to regain solid position in cancer drugs
RE
06/12GSK says vaccine business president to leave by year-end
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
06/16Pulmatrix $PULM Trading Up -5.1%  
06/15$PULM loading for next week 33% play based on charts $GLD $GOLD..
1
06/15Want the latest analyst ratings on $MOTS $TATT $PULM $VLRS $ENT? Get Them Del.. 
06/14$PULM .57 today is a buy day should rise up soon for 50% gain soon .. 
06/13Early-stage study supports value proposition of Pulmatrix's PUR0200; shares a.. 
More tweets
Qtime:87
News from SeekingAlpha
06/15YOUR DAILY PHARMA SCOOP : Wright Receives PMA, Allergan And Corbus Report Positi.. 
06/13Early-stage study supports value proposition of Pulmatrix's PUR0200; shares a.. 
05/11Pulmatrix reports Q1 results 
03/30YOUR DAILY PHARMA SCOOP : Heron Offering, Sorrento Issues Letter To Shareholders.. 
03/29Pulmatrix down 26% premarket on pricing public offering of 23.5M units 
Chart PULMATRIX INC
Duration : Period :
Pulmatrix Inc Technical Analysis Chart | PULM | US74584P1030 | 4-Traders
Technical analysis trends PULMATRIX INC
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 3,50 $
Spread / Average Target 531%
EPS Revisions
Managers
NameTitle
Robert W. Clarke President, Chief Executive Officer & Director
Mark T. Iwicki Chairman
William E. Duke Chief Financial Officer, Treasurer & Secretary
David L. Hava Chief Scientific Officer
James M. Roach Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
PULMATRIX INC-60.64%24
GILEAD SCIENCES-1.97%89 796
VERTEX PHARMACEUTICALS3.44%38 655
REGENERON PHARMACEUTICALS-16.13%33 439
NEUROCRINE BIOSCIENCES, INC.31.87%9 196
GENMAB-6.69%9 076